Patent · US Active

CCN3 and CCN3 peptides and analogs thereof for therapeutic uses

US9114112B2 · kind B2 · utility

4Cited by
0References
8Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 21, 2012
Grant dateAug 25, 2015
Priority date
Expiry dateDec 21, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/475
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.